Taiko Pharmaceutical Co., Ltd. (4574) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Taiko Pharmaceutical Co., Ltd. (4574:JPX), powered by AI.

Current Price
¥260
P/E Ratio
14.2
Market Cap
13.1B
Sector
Healthcare
What is the Taiko Pharmaceutical Co., Ltd. stock price forecast?

Taiko Pharmaceutical Co., Ltd. is currently trading at ¥260. View real-time AI analysis on Alpha Lenz.

What is Taiko Pharmaceutical Co., Ltd. insider trading activity?

View the latest insider trading data for Taiko Pharmaceutical Co., Ltd. on Alpha Lenz.

What is Taiko Pharmaceutical Co., Ltd.'s P/E ratio?

Taiko Pharmaceutical Co., Ltd.'s P/E ratio is 14.2.

Taiko Pharmaceutical Co., Ltd.

JPX · 4574
¥260+7(+2.77%)Market closedJPX regular session 09:00–15:00 JST
Ask about Taiko Pharmaceutical Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Taiko Pharmaceutical Co., Ltd. trades at a P/E of 14.2 (undervalued) with solid ROE of 11.2%.

Ask for details

Company Overview

Taiko Pharmaceutical Co., Ltd. is a distinguished company within the pharmaceutical industry, committed to the research, development, manufacturing, and marketing of pharmaceutical products. This company primarily focuses on the development of drugs that tackle infectious diseases and respiratory conditions, significantly contributing to the healthcare sector. Its product portfolio often includes antiseptics, decongestants, and various hygienic solutions that are crucial in both hospital and consumer settings. With an emphasis on innovation, Taiko Pharmaceutical continually invests in new medical technologies and product improvements to meet evolving healthcare demands. As a player in the pharmaceutical market, the company underscores its role by addressing public health needs and enhancing the quality of life through its medicinal products. Its market significance is evident in the way it supports healthcare providers and consumers in maintaining health standards and combating diseases, thereby influencing the broader pharmaceutical landscape.

CEOMr. Takashi Shibata
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees214

Company Statistics

FY 2025

Profile

¥13,061,360,000Market Cap
¥6,397,000,000Revenue
0.00Shares Out
214Employees

Margins

54.42%Gross
13.77%EBITDA
7.18%Operating
14.98%Pre-Tax
14.43%Net

Valuation

14.15P/E
1.53P/B
2.04EV/Sales
11.10EV/EBITDA
25.61P/FCF

Growth (CAGR)

8.27%Rev 3Yr
-15.60%Rev 5Yr
N/AOp Inc 3Yr
-34.56%Op Inc 5Yr
N/ANet Inc 3Yr
-17.76%Net Inc 5Yr

Returns

7.33%ROA
11.20%ROE
7.65%ROIC

Financial Health

¥4,256,000,000Cash & Cash Equivalents
¥-504,000,000Net Debt
44.05%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Taiko Pharmaceutical Co., Ltd. (ticker: 4574) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 214 employees. Market cap is $13.1B.

The current price is 260 with a P/E ratio of 14.15x and P/B of 1.53x.

ROE is 11.20% and operating margin is 7.18%. Annual revenue is $6.4B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Taiko Pharmaceutical Co., Ltd. (4574) Stock Forecast 2026 ¥260 — Price, Financials & Analyst Targets | Alpha Lenz